You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 330 Combination therapy with stem cell derived natural killer cells and monoclonal antibodies leads to potent ADCC through engagement of endogenouse CD16

Article metrics

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Cellular Therapies
330 Combination therapy with stem cell derived natural killer cells and monoclonal antibodies leads to potent ADCC through engagement of endogenouse CD16

 

Online download statistics by month:

Online download statistics by month: November 2023 to June 2025

AbstractFullPdf
Nov 2023208024
Dec 20235706
Jan 202410402
Feb 20242601
Mar 20242401
Apr 20241602
May 20243401
Jun 20241600
Jul 20242603
Aug 2024800
Sep 20241401
Oct 20241407
Nov 20246005
Dec 20242605
Jan 20254805
Feb 2025903
Mar 2025007
Apr 2025003
May 2025006
Jun 2025203
Total692085